Revisiting the cost-effectiveness of the combine study for alcohol dependent patients: The patient perspective

Medical Care

Volumn 48, Issue 4, 2010, Pages 306-313

  Dunlap, Laura J ^a   Zarkin, Gary A ^a   Bray, Jeremy W ^a   Mills, Michael ^a   Kivlahan, Daniel R ^b   McKay, James R ^c   Latham, Patricia ^d   Tonigan, J Scott ^e  

^a RTI INTERNATIONAL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Alcohol treatment; Cost effectiveness; Patient costs

Indexed keywords

ACAMPROSATE; NALTREXONE; PLACEBO;

ALCOHOLISM; ARTICLE; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; OUTCOME ASSESSMENT; OUTPATIENT; PATIENT TIME COST; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; TIME; UNITED STATES;

ALCOHOLISM; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; FINANCING, PERSONAL; HEALTH EXPENDITURES; HUMANS; PATIENT ACCEPTANCE OF HEALTH CARE; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES;

EID: 77950264384     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e3181ca3d40     Document Type: Article

References (31)

1. Tucker JA, Vuchinich RE, Rippens PD. A factor analytic study of influences on patterns of help-seeking among treated and untreated alcohol dependent persons. J Subst Abuse Treat. 2004;26:237-242.
2. Weisner C, Matzger H, Tam T, et al. Who goes to alcohol and drug treatment? Understanding utilization within the context of insurance. J Stud Alcohol. 2002;63:673-682.
3. Hasin DS, Grant BF. AA and other helpseeking for alcohol problems: former drinkers in the U.S. general population. J Subst Abuse Treat. 1995;7:281-292.
4. Hser Y, Maglione M, Polinsky ML, et al. Predicting drug treatment entry among treatment-seeking individuals. J Subst Abuse Treat. 1998;15:213-220.
5. Yarbroff KR, Warren JL, Knopf K, et al. Estimating patient time costs associated with colorectal cancer care. Med Care. 2005;43:640-648.
6. Shireman TI, Tsevat J, Goldie SJ. Time costs associated with cervical cancer screening. Int J Technol Assess Health Care. 2001;17:146-152.
7. Schulper M, Palmer MK, Heyes A. Costs incurred by patients undergoing advanced colorectal cancer therapy. Pharmacoeconomics. 2000;17: 361-370.
8. Secker-Walker RH, Vacek PM, Hooper GJ, et al. Screening for breast cancer: time, travel and out-of-pocket expenses. J Natl Cancer Inst. 1999;91:702-708.
9. Salome H, French MT, Miller M, et al. Estimating the client costs of addiction treatment: first findings from the client drug abuse treatment cost analysis program (Client DATCAP). Drug Alcohol Depend. 2003; 71:195-206.
10. Anton RF, O'Malley SS, Ciraulo DA, et al; for the COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003-2217.
11. Pettinati HM, Zweben A, Mattson ME. The COMBINE Study: Conceptual, Methodological and Practical Issues in a Clinical Trial That Combined Medication and Behavioral Treatments. Piscataway, NJ: Center of Alcohol Studies, Rutgers University; 2005
12. The COMBINE Study Research Group. Testing combined pharmaco-therapies and behavioral interventions in alcohol dependence: rationale and methods. Alcohol Clin Exp Res. 2003;27:1107-1122.
13. Zarkin GA, Bray JW, Aldridge A, et al. Cost and cost-effectiveness of the COMBINE study for alcohol-dependent patients. Arch Gen Psychiatry. 2008;65:1214-1221.
14. Zarkin GA, Bray JW, Mitra D, et al. Cost methodology of COMBINE. J Stud Alcohol Suppl. 2005:50-55.
15. Bray JW, Zarkin GA, Miller WR, et al. Measuring economic outcomes of alcohol treatment using the Economic Form 90. J Stud Alcohol Drugs. 2007;68:248-255.
16. Miller WR, Del Boca FK. Measurement of drinking behavior using the Form 90 family of instruments. J Stud Alcohol Suppl. 1994;12:112-118.
17. Tonigan JS, Miller WR, Brown JM. The reliability of Form 90: an instrument for assessing alcohol treatment outcome. J Stud Alcohol. 1997;58:358-364.
18. Scheurich A, Müller MJ, Anghelescu I, et al. Reliability and validity of the Form 90 interview. Eur Addict Res. 2005;11:50-56.
19. Gabel J, Claxton G, Gil I, et al. Health benefits in 2005: premium increases slow down, coverage continues to erode. Health Aff. 2005;24: 1273-1280.
20. Sommers JP. Medical Expenditure Panel Survey: co-pays, deductibles, and coinsurance percentages for employer-sponsored health insurance in the non-federal workforce, by industry classification, 2005. August 2007. Agency for Healthcare Research and Quality. Statistical Brief 182. Available at: www.meps.ahrq.gov/mepsweb/data-files/publications/ st182/stat182.pdf. Accessed July 17, 2008.
21. Thomson MicroMedex. RedBook for Windows. Version 61127. Vol.41. Montvale, NJ: Thomson PDR; 2006.
22. Dewan M. Are psychiatrists cost-effective? An analysis of integrated versus split treatment. Am J Psychiatry. 1999;156:324-326.
23. Miller WR, Tonigan JS, Longabaugh R. The Drinker Inventory of Consequences (DrInC): an instrument for assessing adverse consequences of alcohol abuse. In: Test Manual. Project MATCH Monograph Series. Vol.4. Rockville, MD: National Institute on Alcohol Abuse and Alcoholism; 1995.
24. Cisler R, Zweben A. Development of a composite measure for assessing alcohol treatment outcome. Alcohol Clin Exp Res. 1999;23:263-271.
25. Siegel JE, Weinstein MC, Torrance GW. Reporting cost-effectiveness studies and results. In: Gold MR, Siegel JE, Russell LB, et al, eds. Cost Effectiveness of Health and Medicine. New York, NY: Oxford University Press; 1996:276-303.
26. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. New York, NY: Oxford University Press; 2005.
27. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves-facts, fallacies and frequently asked questions. Health Econ. 2004;13:405-414.
28. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10:779-787.
29. Fenwick E, Marshall DA, Levy AR, et al. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation. BMC Health Serv Res. 2006;6:52-59.
30. Tolley G, Kenkel D, Fabian R. Valuing Health for Policy, An Economic Approach. Chicago, IL: The University of Chicago Press; 1994.
31. Juster FT, Stafford FP. The allocation of time: empirical findings, behavioral models, and problems of measurement. J Econ Lit. 1991;29: 471-522.